SNX1 and ovarian carcinoma: It is noteworthy that the phenotypic potency induced by SNX1 overexpression—such as the inhibition of proliferation and the sensitivity to paclitaxel—did not exhibit a simple linear correlation with its protein expression levels in the two ovarian cancer cell lines (A2780 and HEY).